PURPOSE:Prostate cancer is detected with increasing frequency but has a highly variable natural history and prognosis and active surveillance of men with low-risk prostate cancer would benefit greatly from minimally invasive methods to identify progression.
We describe here two novel in vivo metrics of cell proliferation in men with prostate neoplasia.
EXPERIMENTAL DESIGN: Three groups of men drank heavy water, a nonradioactive, stable isotopic tracer for 14 to 28 days: (i) healthy men, (ii) men scheduled for transrectal core needle biopsy, and (iii) men scheduled for radical prostatectomy. Prostate epithelial cells (PEC) were isolated from ejaculated seminal fluid in all subjects. Histologically graded lesions were microdissected from tissue slides obtained from subjects undergoing surgery and proliferation rates were measured from isolated cells via mass spectrometry.
RESULTS: Proliferation rates of seminal PEC in healthy men (0.10%-0.27%/d) were stable on repeat sampling. Rates above 0.34%/d were seen only in patients with cancer where rates increased progressively from normal tissue through benign prostate hyperplasia, prostate intraepithelial neoplasia, and tumor grades III and IV in all subjects. Seminal PEC kinetics correlated highly with the most proliferative microdissected region in each subject (r2 = 0.94).
CONCLUSIONS: Prostate cell proliferation can be measured in vivo from microdissected histopathology sections or noninvasively from seminal fluid where the latter reflects the most proliferative region of the gland. This approach may allow monitoring of progression in men with low-risk prostate cancer.
Written by:
Hayes GM, Simko J, Holochwost D, Kuchinsky K, Busch R, Misell L, Murphy EJ, Carroll P, Chan J, Shinohara K, Hellerstein MK. Are you the author?
KineMed, Inc., Emeryville; Departments of Pathology and Urology, Helen Diller Family Comprehensive Cancer Center, Division of Endocrinology, Department of Medicine, San Francisco General Hospital, University of California at San Francisco; and Department of Nutritional Sciences and Toxicology, University of California at Berkeley, San Francisco, California.
Reference: Clin Cancer Res. 2012 Jun 15;18(12):3250-60.
doi: 10.1158/1078-0432.CCR-11-2988
PubMed Abstract
PMID: 22553345
UroToday.com Prostate Cancer Section